Insider Selling: Evolus (NASDAQ:EOLS) Insider Sells $64,927.75 in Stock

Evolus, Inc. (NASDAQ:EOLS) insider David Moatazedi sold 13,669 shares of the stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $4.75, for a total value of $64,927.75. Following the sale, the insider directly owned 604,700 shares in the company, valued at $2,872,325. This represents a 2.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

David Moatazedi also recently made the following trade(s):

• On Tuesday, March 17th, David Moatazedi sold 116,720 shares of Evolus stock. The shares were sold at an average price of $4.89, for a total value of $570,760.80.
• On Monday, December 22nd, David Moatazedi sold 10,539 shares of Evolus stock. The stock was sold at an average price of $7.15, for a total value of $75,353.85.

Evolus Stock Down 4.5%

Evolus stock opened at $4.64 on Monday. The firm has a market cap of $301.88 million, a price-to-earnings ratio of -5.73 and a beta of 1.02. Evolus, Inc. has a 52 week low of $4.09 and a 52 week high of $13.30. The business’s 50-day moving average price is $4.79 and its 200 day moving average price is $6.03.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported $0.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.09). The business had revenue of $90.30 million during the quarter, compared to the consensus estimate of $89.58 million. Equities analysts expect that Evolus, Inc. will post -0.61 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently commented on EOLS shares. Needham & Company LLC restated a “hold” rating on shares of Evolus in a research report on Wednesday, December 24th. Mizuho set a $15.00 price objective on shares of Evolus in a research report on Wednesday, February 4th. Weiss Ratings reissued a “sell (e+)” rating on shares of Evolus in a research note on Monday, December 22nd. Wall Street Zen cut Evolus from a “buy” rating to a “hold” rating in a research report on Sunday, March 15th. Finally, HC Wainwright cut their price target on Evolus from $20.00 to $13.00 and set a “buy” rating for the company in a research note on Tuesday, February 3rd. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Evolus presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Institutional Investors Weigh In On Evolus

Institutional investors have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Evolus by 5.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,289 shares of the company’s stock worth $400,000 after acquiring an additional 1,838 shares during the period. Millennium Management LLC increased its stake in shares of Evolus by 1.7% during the first quarter. Millennium Management LLC now owns 1,392,028 shares of the company’s stock worth $16,746,000 after purchasing an additional 23,605 shares in the last quarter. Jones Financial Companies Lllp purchased a new stake in shares of Evolus during the first quarter worth about $158,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Evolus by 36.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,565 shares of the company’s stock worth $1,883,000 after purchasing an additional 41,513 shares during the last quarter. Finally, Jane Street Group LLC raised its position in shares of Evolus by 484.8% during the 1st quarter. Jane Street Group LLC now owns 69,947 shares of the company’s stock worth $841,000 after purchasing an additional 57,987 shares during the last quarter. Institutional investors and hedge funds own 90.69% of the company’s stock.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.